(Reuters) – Legend of Biotech Corp. (O :), a cell therapy unit listed in Hong Kong Genscript Biotech Corp. (HK 🙂 said on Sunday that Frank Zhang had been appointed Chief Executive Officer and that he would step down as CEO of Genscript.
Legend's outgoing CEO, Xu, resigned for personal reasons, according to the US-based biotech company. Xu also resigned from Legend's board.
Zhang, who founded Legend in 2014, has been the CEO for five years. He will continue his position and take over responsibility as CEO from now on.
The change of management took place about two months after the company's US stock market debut. Legend raised $ 423.8 million on the IPO.
Disclaimer: Fusion Media would like to remind you that the data contained on this website is not necessarily real-time or correct. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. Therefore, prices may not be accurate and may differ from the actual market price. This means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media assumes no responsibility for any trade losses that you may incur from using this data.
Fusion Media or persons dealing with Fusion Media are not liable for any loss or damage caused by reliance on the information contained on this website such as data, offers, diagrams and buy / sell signals. Please be fully informed about the risks and costs associated with trading on the financial markets. This is one of the most risky forms of investment that is possible.